Your browser doesn't support javascript.
loading
Downregulation of Polo-like kinase-1 (PLK-1) expression is associated with poor clinical outcome in uveal melanoma patients.
Berus, Tomasz; Markiewicz, Anna; Kobylinska, Katarzyna; Biecek, Przemyslaw; Orlowska-Heitzman, Jolanta; Romanowska-Dixon, Bozena; Donizy, Piotr.
Afiliação
  • Berus T; Department of Ophthalmology, 4th Military Clinical Hospital with Polyclinic, Weigla 5, 50-981 Wroclaw, Poland. tberus@op.pl.
  • Markiewicz A; Department of Ophthalmology and Ocular Oncology, the Jagiellonian University, Medical College, Kopernika 38, 31-501 Krakow, Poland.
  • Kobylinska K; Faculty of Mathematics, Informatics and Mechanics University of Warsaw, Warsaw, Poland.
  • Biecek P; Faculty of Mathematics, Informatics and Mechanics University of Warsaw, Warsaw, Poland.
  • Orlowska-Heitzman J; Department of Pathomorphology, the Jagiellonian University, Medical College, Grzegorzecka 16, 31-531 Krakow, Poland.
  • Romanowska-Dixon B; Department of Ophthalmology and Ocular Oncology, the Jagiellonian University, Medical College, Kopernika 38, 31-501 Krakow, Poland.
  • Donizy P; Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.
Folia Histochem Cytobiol ; 58(2): 108-116, 2020.
Article em En | MEDLINE | ID: mdl-32602935
ABSTRACT

INTRODUCTION:

Uveal melanoma (UM) is the most common primary eye tumour in adults. Distant metastases are seen in 50% of cases regardless of treatment, which contributes to high mortality rates. Polo-like kinase-1 (PLK-1) is a protein regulator of mitotic entry and cytokinesis. Increased PLK-1 expression has been shown in different tumours, which makes its inhibition a potential treatment target. To date, no study has been published to discuss the prognostic role of PLK-1 expression in patients with uveal melanoma. MATERIAL AND

METHODS:

We assessed by immunohistochemistry PLK-1 expression in uveal melanoma cells collected in 158 patients treated by primary enucleation. We determined the correlation between PLK-1 levels evaluated by the immunoreactivity scale (IRS) method and detailed clinical as well as histological parameters. Additionally, we determined the association between PLK-1 expression levels and long-term prognosis.

RESULTS:

Elevated PLK-1 expression in tumour cells, defined as IRS > 2, was observed in 70% (111/158) of cases, whereas low expression or no expression was seen in the remaining 30% (47/158) of patients. There was a significant correlation between low PLK-1 expression and a higher clinical tumour stage (pT, p = 0.04) as well as a higher AJCC prognostic stage group (p = 0.037). We observed an inverse correlation between PLK-1 expression and tumour cell pigment content (p = 0.0019). There was no correlation between PLK-1 expression and other histological parameters such as mitotic rate or histological subtype. The Kaplan-Meier's analysis demonstrated that low PLK-1 expression was associated with significantly reduced overall survival (p = 0.0058). A similar trend, albeit not significant, was observed for disease-free survival (p = 0.088).

CONCLUSIONS:

Downregulated PLK-1 expression is a negative prognostic factor in uveal melanoma. It warrants further, multicentre research on prognostic role of PLK-1 expression and possibility of PLK-1 inhibition in uveal melanoma.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uveais / Proteínas Proto-Oncogênicas / Proteínas Serina-Treonina Quinases / Proteínas de Ciclo Celular / Melanoma Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uveais / Proteínas Proto-Oncogênicas / Proteínas Serina-Treonina Quinases / Proteínas de Ciclo Celular / Melanoma Idioma: En Ano de publicação: 2020 Tipo de documento: Article